These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 25010863)

  • 1. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
    Gammons MV; Lucas R; Dean R; Coupland SE; Oltean S; Bates DO
    Br J Cancer; 2014 Jul; 111(3):477-85. PubMed ID: 25010863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
    Mavrou A; Brakspear K; Hamdollah-Zadeh M; Damodaran G; Babaei-Jadidi R; Oxley J; Gillatt DA; Ladomery MR; Harper SJ; Bates DO; Oltean S
    Oncogene; 2015 Aug; 34(33):4311-9. PubMed ID: 25381816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1.
    Wagner KD; El Maï M; Ladomery M; Belali T; Leccia N; Michiels JF; Wagner N
    Cells; 2019 Jan; 8(1):. PubMed ID: 30641926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.
    Amin EM; Oltean S; Hua J; Gammons MV; Hamdollah-Zadeh M; Welsh GI; Cheung MK; Ni L; Kase S; Rennel ES; Symonds KE; Nowak DG; Royer-Pokora B; Saleem MA; Hagiwara M; Schumacher VA; Harper SJ; Hinton DR; Bates DO; Ladomery MR
    Cancer Cell; 2011 Dec; 20(6):768-80. PubMed ID: 22172722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.
    Nowak DG; Amin EM; Rennel ES; Hoareau-Aveilla C; Gammons M; Damodoran G; Hagiwara M; Harper SJ; Woolard J; Ladomery MR; Bates DO
    J Biol Chem; 2010 Feb; 285(8):5532-40. PubMed ID: 19906640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
    Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
    Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD.
    Gammons MV; Fedorov O; Ivison D; Du C; Clark T; Hopkins C; Hagiwara M; Dick AD; Cox R; Harper SJ; Hancox JC; Knapp S; Bates DO
    Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6052-62. PubMed ID: 23887803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.
    Hatcher JM; Wu G; Zeng C; Zhu J; Meng F; Patel S; Wang W; Ficarro SB; Leggett AL; Powell CE; Marto JA; Zhang K; Ki Ngo JC; Fu XD; Zhang T; Gray NS
    Cell Chem Biol; 2018 Apr; 25(4):460-470.e6. PubMed ID: 29478907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma.
    Pritchard-Jones RO; Dunn DB; Qiu Y; Varey AH; Orlando A; Rigby H; Harper SJ; Bates DO
    Br J Cancer; 2007 Jul; 97(2):223-30. PubMed ID: 17595666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
    Supradit K; Boonsri B; Duangdara J; Thitiphatphuvanon T; Suriyonplengsaeng C; Kangsamaksin T; Janvilisri T; Tohtong R; Yacqub-Usman K; Grabowska AM; Bates DO; Wongprasert K
    Toxicol In Vitro; 2022 Aug; 82():105385. PubMed ID: 35568131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.
    Peiris-Pagès M; Harper SJ; Bates DO; Ramani P
    J Pathol; 2010 Oct; 222(2):138-47. PubMed ID: 20662003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.
    Batson J; Toop HD; Redondo C; Babaei-Jadidi R; Chaikuad A; Wearmouth SF; Gibbons B; Allen C; Tallant C; Zhang J; Du C; Hancox JC; Hawtrey T; Da Rocha J; Griffith R; Knapp S; Bates DO; Morris JC
    ACS Chem Biol; 2017 Mar; 12(3):825-832. PubMed ID: 28135068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.
    Nowak DG; Woolard J; Amin EM; Konopatskaya O; Saleem MA; Churchill AJ; Ladomery MR; Harper SJ; Bates DO
    J Cell Sci; 2008 Oct; 121(Pt 20):3487-95. PubMed ID: 18843117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of IL-8 induced angiogenesis in uveal melanoma.
    Lattanzio L; Tonissi F; Torta I; Gianello L; Russi E; Milano G; Merlano M; Lo Nigro C
    Invest New Drugs; 2013 Oct; 31(5):1107-14. PubMed ID: 23912257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
    Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
    Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.
    Oltean S; Gammons M; Hulse R; Hamdollah-Zadeh M; Mavrou A; Donaldson L; Salmon AH; Harper SJ; Ladomery MR; Bates DO
    Biochem Soc Trans; 2012 Aug; 40(4):831-5. PubMed ID: 22817743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
    Wahid M; Pratoomthai B; Egbuniwe IU; Evans HR; Babaei-Jadidi R; Amartey JO; Erdelyi V; Yacqub-Usman K; Jackson AM; Morris JC; Patel PM; Bates DO
    Cancer Immunol Immunother; 2023 Dec; 72(12):4001-4014. PubMed ID: 37973660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.
    Merdzhanova G; Gout S; Keramidas M; Edmond V; Coll JL; Brambilla C; Brambilla E; Gazzeri S; Eymin B
    Oncogene; 2010 Sep; 29(39):5392-403. PubMed ID: 20639906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1.
    Belali T; Wodi C; Clark B; Cheung MK; Craig TJ; Wheway G; Wagner N; Wagner KD; Roberts S; Porazinski S; Ladomery M
    Biochim Biophys Acta Gene Regul Mech; 2020 Dec; 1863(12):194642. PubMed ID: 33017668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
    Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
    J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.